Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well nivolumab and ibrutinib works in
treating patients with central nervous system lymphoma that has come back or does not respond
to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving nivolumab and ibrutinib may work better in treating patients
with central nervous system lymphoma.